Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus pemetrexed in platinum-unfit EGFR exon 20 insertion NSCLC
2025-520676-26-00Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Dec 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Objective response rate. Planned start Dec 2025; status: authorised.
02
Drugs
amivantamabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-520676-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520676-26-00.